Panaccione R, Rutgeerts P, Sandborn W J, Feagan B, Schreiber S, Ghosh S
Department of Medicine, University of Calgary, Calgary, AB, Canada.
Aliment Pharmacol Ther. 2008 Sep 15;28(6):674-88. doi: 10.1111/j.1365-2036.2008.03753.x.
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine, which frequently require surgery for complications or failure of medical therapy.
To seek evidence and provide direction for clinicians on optimal strategies to enable steroid free remission in inflammatory bowel disease.
Scientific literature was reviewed using MEDLINIE with a specific focus on medical therapies for inducing and maintaining remission of CD and UC. The results were discussed at a roundtable meeting to reach a consensus on key issues.
Several therapies have demonstrated efficacy for the treatment of active, moderate-to-severe CD and UC. These include agents, which induce remission [corticosteroids, infliximab and adalimumab (CD only)] or maintain remission and spare corticosteroids [azathioprine, mercaptopurine, methotrexate (CD only), infliximab and adalimumab (CD only)]. Wide variability exists in the use of these agents.
Treatment strategy algorithms are developed for use of these therapies that maximize remission and minimize corticosteroid dependence in patients with moderate-to-severe CD and UC.
克罗恩病(CD)和溃疡性结肠炎(UC)是肠道慢性炎症性疾病,常因并发症或药物治疗失败而需要手术。
寻找证据并为临床医生提供关于在炎症性肠病中实现无类固醇缓解的最佳策略的指导。
使用医学文献数据库(MEDLINIE)对科学文献进行综述,特别关注诱导和维持CD及UC缓解的药物治疗。在一次圆桌会议上讨论了结果,以就关键问题达成共识。
几种疗法已证明对治疗活动期、中重度CD和UC有效。这些包括诱导缓解的药物[皮质类固醇、英夫利昔单抗和阿达木单抗(仅用于CD)]或维持缓解并减少皮质类固醇使用的药物[硫唑嘌呤、巯嘌呤、甲氨蝶呤(仅用于CD)、英夫利昔单抗和阿达木单抗(仅用于CD)]。这些药物的使用存在很大差异。
针对这些疗法制定了治疗策略算法,以在中重度CD和UC患者中最大限度地实现缓解并最小化对皮质类固醇的依赖。